Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INFINITY study of tremelimumab + durvalumab for resectable MSI-high gastric or gastroesophageal junction cancer
2024-518842-26-00Phase 2Authorised
- Sponsor
- G.O.N.O. - Gruppo Oncologico del Nord Ovest
- Start
- Jan 2025
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tremelimumab and durvalumab in gastric cancer (GC) and esophagogastric junction cancer (2 cohorts), sponsored by G.O.N.O. - Gruppo Oncologico del Nord Ovest. Primary endpoints: Pathological complete response and ctDNA negativity and 2-year complete response rate. Planned start Jan 2025; status: authorised.
02
Drugs
tremelimumabdurvalumab
03
Conditions
gastric cancer (GC)esophagogastric junction cancer
Beyond the preview
Go deeper on 2024-518842-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518842-26-00.